Seeking Alpha

Viropharma (VPHM -7%) finishes lower after its Q1 earnings missed on the top line. Net sales...

Viropharma (VPHM -7%) finishes lower after its Q1 earnings missed on the top line. Net sales declined Q/Q, which was driven by a decline in Vancocin revenues due to generic competition. Vancocin net sales during the three months were $4M compared to $66M in the year prior. The company also reaffirmed FY13 revenues towards the low end of estimates, expecting to earn between $440M - $465M, versus the Street consensus of $464M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|